SG11201908744PA - Anti-c5a antibodies and uses thereof - Google Patents

Anti-c5a antibodies and uses thereof

Info

Publication number
SG11201908744PA
SG11201908744PA SG11201908744PA SG11201908744PA SG 11201908744P A SG11201908744P A SG 11201908744PA SG 11201908744P A SG11201908744P A SG 11201908744PA SG 11201908744P A SG11201908744P A SG 11201908744PA
Authority
SG
Singapore
Prior art keywords
international
philadelphia
pct
complement
apt
Prior art date
Application number
Inventor
Wenchao Song
Takashi Miwa
Sayaka Sato
Damodar Gullipalli
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of SG11201908744PA publication Critical patent/SG11201908744PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

NRC 49.1160100.4i . l aitib 02 -it- Mil 102 10.3 104 104 10 10-7 o 0 4 0.0 10 NR (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT o mum °nolo UI n ono oimIE (10) International Publication Number WO 2018/175833 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/18 (2006.01) A61K 39/00 (2006.01) C07K 16/28 (2006.01) A61K 45/06 (2006.01) C07K 14/00 (2006.01) (21) International Application Number: PCT/US2018/023927 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/475,573 23 March 2017 (23.03.2017) US (71) Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104 (US). (72) Inventors: SONG, Wenchao; 213 Cornell Drive, Bryn Mawr, PA 19010 (US). MIWA, Takashi; 191 Presiden- tial Blvd., Unit 323, Bala Cynwyd, PA 19004 (US). SA- TO, Sayaka; 2130 Locust Street, Apt. #A1, Philadelphia, PA 19103 (US). GULLIPALLI, Damodar; 4007 Wood- land Avenue, Apt. B, Philadelphia, PA 19106 (US). (74) Agent: HAAS, Dennis, L. et al.; Riverside Law, LLP, Glenhardie Corporate Center, 1285 Drummers Lane, Suite 202, Wayne, PA 19087 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ANTI-05A ANTIBODIES AND USES THEREOF 7Al2 Control anti-05 mAb 00 Figure 1 N 1-1 1-1 (57) : This invention relates to inhibition of the complement signaling using anti-05a antibody. Specifically, the invention © relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the C individual with an anti-05a antibody. [Continued on next page] WO 2018/175833 Al MIDE111111011111 1111E111E31111111111111111111111111111111101111111111 Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201908744P 2017-03-23 2018-03-23 Anti-c5a antibodies and uses thereof SG11201908744PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762475573P 2017-03-23 2017-03-23
PCT/US2018/023927 WO2018175833A1 (en) 2017-03-23 2018-03-23 Anti-c5a antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11201908744PA true SG11201908744PA (en) 2019-10-30

Family

ID=63585782

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908744P SG11201908744PA (en) 2017-03-23 2018-03-23 Anti-c5a antibodies and uses thereof

Country Status (13)

Country Link
US (2) US11274146B2 (en)
EP (1) EP3600421A4 (en)
JP (2) JP7251792B2 (en)
KR (1) KR20190132665A (en)
CN (1) CN110709101B (en)
AU (1) AU2018237300A1 (en)
BR (1) BR112019019595A2 (en)
CA (1) CA3057146A1 (en)
EA (1) EA201992248A1 (en)
IL (1) IL269428A (en)
MX (1) MX2019011252A (en)
SG (1) SG11201908744PA (en)
WO (1) WO2018175833A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3349773A4 (en) 2015-09-14 2019-05-01 Cincinnati Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
JP7102353B2 (en) 2016-06-14 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Anti-C5 antibodies and their use
EP3592386A4 (en) * 2017-03-06 2021-01-13 The Trustees Of The University Of Pennsylvania Anti-c5 antibodies and uses thereof
WO2019118556A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
WO2020247703A1 (en) * 2019-06-06 2020-12-10 Children's Hospital Medical Center Methods and compositions for treatment of neurodegeneration
TW202208427A (en) * 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 Humanized anti-c5a antibodies
WO2023050233A1 (en) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Humanized anti-c5a antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
ATE360441T1 (en) 2001-08-17 2007-05-15 Tanox Inc COMPLEMENT INHIBITORS THAT BIND TO C5 AND C5A WITHOUT INHIBITING THE FORMATION OF C5B
EP1878441B1 (en) 2001-08-17 2018-01-24 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
JP2011515073A (en) * 2008-02-20 2011-05-19 ジーツー インフラメイション プロプライエタリー リミテッド Humanized anti-C5aR antibody
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
WO2010129917A2 (en) 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
ES2566602T3 (en) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
PT2563813E (en) 2010-04-30 2015-11-26 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
US8206715B2 (en) 2010-05-04 2012-06-26 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
SG10201506782XA (en) * 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
CA2822288A1 (en) 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
PT2699601T (en) 2011-04-21 2018-04-05 Domantis Ltd Antibody polypeptides that antagonize cd40
JP6001557B2 (en) * 2011-04-28 2016-10-05 Ｓｂｉバイオテック株式会社 Anti-human receptor protein tyrosine phosphatase sigma antibody
US9828635B2 (en) * 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
JP7209464B2 (en) 2014-07-10 2023-01-20 ウニヴェルズィテート・ツューリヒ Immunostimulatory monoclonal antibody against human interleukin-2
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3592386A4 (en) * 2017-03-06 2021-01-13 The Trustees Of The University Of Pennsylvania Anti-c5 antibodies and uses thereof
TW202208427A (en) * 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 Humanized anti-c5a antibodies

Also Published As

Publication number Publication date
KR20190132665A (en) 2019-11-28
US20200148754A1 (en) 2020-05-14
CN110709101A (en) 2020-01-17
RU2019133479A (en) 2021-04-23
JP2020511505A (en) 2020-04-16
US11274146B2 (en) 2022-03-15
CN110709101B (en) 2024-05-07
EA201992248A1 (en) 2020-02-06
BR112019019595A2 (en) 2020-04-14
US20220153824A1 (en) 2022-05-19
WO2018175833A1 (en) 2018-09-27
AU2018237300A1 (en) 2019-10-17
IL269428A (en) 2019-11-28
CA3057146A1 (en) 2018-09-27
EP3600421A1 (en) 2020-02-05
MX2019011252A (en) 2020-01-23
JP2022183224A (en) 2022-12-08
RU2019133479A3 (en) 2021-11-24
EP3600421A4 (en) 2021-01-06
JP7251792B2 (en) 2023-04-04

Similar Documents

Publication Publication Date Title
SG11201908744PA (en) Anti-c5a antibodies and uses thereof
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201810149VA (en) Anti hla-g specific antibodies
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201901899PA (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201908051RA (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201907369TA (en) Anti-factor d antibodies and uses thereof
SG11201809789SA (en) Dna monoclonal antibodies targeting checkpoint molecules
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201900442PA (en) Sorting of t lymphocytes in a microfluidic device
SG11201407564TA (en) St2 antigen binding proteins
SG11201809764XA (en) Humanized anti-il-1r3 antibodies
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201810525XA (en) Anti-gitr antibodies and uses thereof